In a report released yesterday, Joel Beatty from Robert W. Baird maintained a Buy rating on Praxis Precision Medicines (PRAX – Research ...

Third Quarter 2024 Results Key Financial Results Net loss: US$51.9m ...

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; ...

Praxis management will also be participating in a fireside chat at the Guggenheim Securities Inaugural Healthcare Innovation Conference, taking place at the InterContinental Boston Hotel in Boston, MA ...

Praxis International Index Fund earns an Average Process Pillar rating. Morningstar's algorithmically assigned Passive Process ratings are first formulated by comparing the historical efficacy of ...

Proponents of the “Network State” seek to create privately owned, anarcho-capitalist, “autonomous” cities—the likes of which will be the urban planning equivalent of what cryptocurrency ...

Entrepreneur Dryden Brown said he has secured $525 million in milestone-based financing to develop Praxis, one of a number of tech utopia proposals under way around the world. Brown, the 28-year ...

Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.75 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $2.70 per share a year ago.

在一场令人瞩目的市场势头中，Praxis Precision Medicines Inc股价已达到52周新高，股价交易至75.87美元。这一峰值对于专注于中枢神经系统疾病治疗的生物制药公司来说是一个重要里程碑。过去一年，Praxis股价出现了非凡的增长，一年期变化数据显示惊人的362.67%涨幅。投资者对公司潜力的信心增强，推动股价达到新高，公司的表现超出预期并吸引了市场的关注。

Abu Dhabi, UAE – Praxis Global Alliance has released a comprehensive report titled “Transforming UAE Healthcare Through ...

英为财情Investing.com - Praxis Precision (NASDAQ: PRAX)星期三发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-2.75，总营收为$302K，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$328.56K，每股收益为$-1.99. 今年 ...